Cargando…

Letter to the Editor Regarding ‘Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis’

Detalles Bibliográficos
Autores principales:	Luger, Thomas, Ranjan, Sandip
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2021
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8018911/ https://www.ncbi.nlm.nih.gov/pubmed/33660231 http://dx.doi.org/10.1007/s13555-021-00503-1

Ejemplares similares

Response to the Letter to the Editor Regarding “Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systemic Literature Review and Network Meta-Analysis”
por: Fahrbach, Kyle, et al.
Publicado: (2021)

Crisaborole Ointment Improves Quality of Life of Patients with Mild to Moderate Atopic Dermatitis and Their Families
por: Simpson, Eric L., et al.
Publicado: (2018)

Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Correction to: Crisaborole Ointment, 2%, for Treatment of Patients with Mild-to-Moderate Atopic Dermatitis: Systematic Literature Review and Network Meta-Analysis
por: Fahrbach, Kyle, et al.
Publicado: (2020)

Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups
por: Callender, Valerie D., et al.
Publicado: (2019)

Improvement in disease severity and pruritus outcomes with crisaborole ointment, 2%, by baseline atopic dermatitis severity in children and adolescents with mild‐to‐moderate atopic dermatitis
por: Eichenfield, Lawrence F., et al.
Publicado: (2020)

Subgroup Analysis of Crisaborole for Mild-to-Moderate Atopic Dermatitis in Children Aged 2 to < 18 Years
por: Luger, Thomas A., et al.
Publicado: (2022)

Crisaborole for atopic dermatitis
Publicado: (2019)

Matching-Adjusted Indirect Comparison of Crisaborole Ointment 2% vs. Topical Calcineurin Inhibitors in the Treatment of Patients with Mild-to-Moderate Atopic Dermatitis
por: Thom, Howard, et al.
Publicado: (2021)

Impact of Crisaborole on Sleep Outcomes in Pediatric Patients with Mild-to-Moderate Atopic Dermatitis
por: Fowler, Joseph, et al.
Publicado: (2023)

Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study
por: Eichenfield, Lawrence F., et al.
Publicado: (2023)

Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Repigmentation in a patient with vitiligo on crisaborole 2% ointment
por: Tam, Idy, et al.
Publicado: (2021)

Translating the Investigator’s Static Global Assessment to the Eczema Area and Severity Index in Studies of Crisaborole for Atopic Dermatitis
por: Thyssen, Jacob P., et al.
Publicado: (2021)

Correction to: Efficacy and Safety Trends with Continuous, Long-Term Crisaborole Use in Patients Aged ≥ 2 Years with Mild-to-Moderate Atopic Dermatitis
por: Geng, Bob, et al.
Publicado: (2021)

Clinical efficacy evaluation of crisaborole ointment in the treatment of vulvar leukoplakia
por: Li, Lijun
Publicado: (2023)

Tacrolimus ointment in the management of atopic dermatitis
por: Baldo, Antonello, et al.
Publicado: (2009)

Crisaborole Topical Ointment, 2% in Patients Ages 2 to 17 Years with Atopic Dermatitis: A Phase 1b, Open‐Label, Maximal‐Use Systemic Exposure Study
por: Zane, Lee T., et al.
Publicado: (2016)

Crisaborole Inhibits Itch and Pain by Preventing Neutrophil Infiltration in a Mouse Model of Atopic Dermatitis
por: PAVLENKO, Darya, et al.
Publicado: (2023)

Evaluating the Efficacy of Crisaborole Using the Atopic Dermatitis Severity Index and Percentage of Affected Body Surface Area
por: SILVERBERG, Jonathan I., et al.
Publicado: (2020)

Letter to The Editor on ‘Evaluation of antimicrobial textiles for atopic dermatitis’
por: Kopera, D.
Publicado: (2019)

Safety, Effectiveness, and Pharmacokinetics of Crisaborole in Infants Aged 3 to < 24 Months with Mild-to-Moderate Atopic Dermatitis: A Phase IV Open-Label Study (CrisADe CARE 1)
por: Schlessinger, Joel, et al.
Publicado: (2020)

Characteristics of Atopic Dermatitis Patients Treated with Crisaborole: Real-World Data from a Large Healthcare Provider Database in Israel
por: Weil, Clara, et al.
Publicado: (2022)

A phase 2b, randomized, double‐blind, multicenter, vehicle‐controlled study to assess the efficacy and safety of two crisaborole regimens in Japanese patients aged 2 years and older with mild‐to‐moderate atopic dermatitis
por: Fujita, Kayo, et al.
Publicado: (2021)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

Paediatric atopic eczema (atopic dermatitis) in South Africa: A practical algorithm for the management of mild-to-moderate disease in daily clinical practice
por: Kannenberg, Susanna M., et al.
Publicado: (2020)

Knuckle Pads Successfully Treated with 2% Crisaborole Ointment Combined with Triamcinolone Acetonide and Neomycin Plaster: A Case Report
por: Liang, Yimin, et al.
Publicado: (2023)

Anti-Inflammatory Effect of Qingpeng Ointment in Atopic Dermatitis-Like Murine Model
por: Li, Yun-Zhu, et al.
Publicado: (2013)

Tacrolimus ointment for the treatment of adult and pediatric atopic dermatitis: Review on safety and benefits
por: Ohtsuki, Mamitaro, et al.
Publicado: (2018)

Evaluation of a Pseudoceramide Moisturizer in Patients with Mild-to-Moderate Atopic Dermatitis
por: Seghers, Amelie Clementine, et al.
Publicado: (2014)

New Cosmetic Formulation for the Treatment of Mild to Moderate Infantile Atopic Dermatitis
por: de Lucas, Raúl, et al.
Publicado: (2019)

Tolerability of Crisaborole Ointment for Application on Sensitive Skin Areas: A Randomized, Double-Blind, Vehicle-Controlled Study in Healthy Volunteers
por: Zane, Lee T., et al.
Publicado: (2016)

Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Compound traditional Chinese medicine dermatitis ointment ameliorates inflammatory responses and dysregulation of itch-related molecules in atopic dermatitis
por: Zhang, Rongrong, et al.
Publicado: (2022)

Correction to: Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2023)

Letter to Editor Regarding the OCEAN Study [Letter]
por: Yawn, Barbara P, et al.
Publicado: (2021)

The microbiome in patients with atopic dermatitis
por: Paller, Amy S., et al.
Publicado: (2018)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

Letter to the Editor Regarding Vaping Article
por: Spitz, Rabbi Yehuda
Publicado: (2019)

Systemic Tofacitinib Concentrations in Adult Patients With Atopic Dermatitis Treated With 2% Tofacitinib Ointment and Application to Pediatric Study Planning
por: Purohit, Vivek S., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_8adqn1t2t1mu77v1rr17d1gcm2